335 related articles for article (PubMed ID: 26631891)
1. Cerebral Venous Thromboembolism in Antiphospholipid Syndrome Successfully Treated with the Combined Use of an Anti-Xa Inhibitor and Corticosteroid.
Sugie M; Iizuka N; Shimizu Y; Ichikawa H
Intern Med; 2015; 54(23):3051-6. PubMed ID: 26631891
[TBL] [Abstract][Full Text] [Related]
2. Rivaroxaban limits complement activation compared with warfarin in antiphospholipid syndrome patients with venous thromboembolism.
Arachchillage DR; Mackie IJ; Efthymiou M; Chitolie A; Hunt BJ; Isenberg DA; Khamashta M; Machin SJ; Cohen H
J Thromb Haemost; 2016 Nov; 14(11):2177-2186. PubMed ID: 27541499
[TBL] [Abstract][Full Text] [Related]
3. Rivaroxaban in antiphospholipid syndrome (RAPS) protocol: a prospective, randomized controlled phase II/III clinical trial of rivaroxaban versus warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE.
Cohen H; Doré CJ; Clawson S; Hunt BJ; Isenberg D; Khamashta M; Muirhead N;
Lupus; 2015 Sep; 24(10):1087-94. PubMed ID: 25940537
[TBL] [Abstract][Full Text] [Related]
4. Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial.
Cohen H; Hunt BJ; Efthymiou M; Arachchillage DR; Mackie IJ; Clawson S; Sylvestre Y; Machin SJ; Bertolaccini ML; Ruiz-Castellano M; Muirhead N; Doré CJ; Khamashta M; Isenberg DA;
Lancet Haematol; 2016 Sep; 3(9):e426-36. PubMed ID: 27570089
[TBL] [Abstract][Full Text] [Related]
5. Rivaroxaban use in patients with antiphospholipid syndrome and previous venous thromboembolism.
Sciascia S; Breen K; Hunt BJ
Blood Coagul Fibrinolysis; 2015 Jun; 26(4):476-7. PubMed ID: 25923780
[No Abstract] [Full Text] [Related]
6. Efficacy and safety of rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome: Rationale and design of the Trial on Rivaroxaban in AntiPhospholipid Syndrome (TRAPS) trial.
Pengo V; Banzato A; Bison E; Zoppellaro G; Padayattil Jose S; Denas G
Lupus; 2016 Mar; 25(3):301-6. PubMed ID: 26466613
[TBL] [Abstract][Full Text] [Related]
7. Outcomes in patients with nontriple antiphospholipid syndrome (APS) anticoagulated with rivaroxaban.
Htut TW; Milne D; Khan MM; Watson HG
Int J Lab Hematol; 2021 Oct; 43(5):e252-e253. PubMed ID: 33470532
[No Abstract] [Full Text] [Related]
8. Rivaroxaban Versus Vitamin K Antagonist in Antiphospholipid Syndrome.
Ann Intern Med; 2019 Nov; 171(10):. PubMed ID: 31610579
[No Abstract] [Full Text] [Related]
9. [Not Available].
Bauersachs R; Schellong S; Stücker M; Oldenburg J; Kalka C; Scholz U; Lindhoff-Last E
Hamostaseologie; 2019 Aug; 39(3):298-300. PubMed ID: 31404932
[No Abstract] [Full Text] [Related]
10. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome.
Pengo V; Denas G; Zoppellaro G; Jose SP; Hoxha A; Ruffatti A; Andreoli L; Tincani A; Cenci C; Prisco D; Fierro T; Gresele P; Cafolla A; De Micheli V; Ghirarduzzi A; Tosetto A; Falanga A; Martinelli I; Testa S; Barcellona D; Gerosa M; Banzato A
Blood; 2018 Sep; 132(13):1365-1371. PubMed ID: 30002145
[TBL] [Abstract][Full Text] [Related]
11. Increased risk of thrombosis in antiphospholipid syndrome patients treated with direct oral anticoagulants. Results from an international patient-level data meta-analysis.
Dufrost V; Risse J; Reshetnyak T; Satybaldyeva M; Du Y; Yan XX; Salta S; Gerotziafas G; Jing ZC; Elalamy I; Wahl D; Zuily S
Autoimmun Rev; 2018 Oct; 17(10):1011-1021. PubMed ID: 30103045
[TBL] [Abstract][Full Text] [Related]
12. After failure with acenocoumarol, rivaroxaban in antiphospholipid syndrome: A report of 2 cases.
Mateos Rodríguez JJ; Bellido D; Castro D; Portillo Sánchez J; Vanegas R; Núñez García A
Reumatol Clin (Engl Ed); 2019; 15(5):e33-e35. PubMed ID: 28546102
[TBL] [Abstract][Full Text] [Related]
13. Rivaroxaban Versus Vitamin K Antagonist in Antiphospholipid Syndrome: A Randomized Noninferiority Trial.
Ordi-Ros J; Sáez-Comet L; Pérez-Conesa M; Vidal X; Riera-Mestre A; Castro-Salomó A; Cuquet-Pedragosa J; Ortiz-Santamaria V; Mauri-Plana M; Solé C; Cortés-Hernández J
Ann Intern Med; 2019 Nov; 171(10):685-694. PubMed ID: 31610549
[TBL] [Abstract][Full Text] [Related]
14. Retrospective comparison of low molecular weight heparin vs. warfarin vs. oral Xa inhibitors for the prevention of recurrent venous thromboembolism in oncology patients: The Re-CLOT study.
Alzghari SK; Seago SE; Garza JE; Hashimie YF; Baty KA; Evans MF; Shaver C; Herrington JD
J Oncol Pharm Pract; 2018 Oct; 24(7):494-500. PubMed ID: 28714376
[TBL] [Abstract][Full Text] [Related]
15. Recurrent venous thromboembolism after discontinuation of rivaroxaban therapy in a patient with antiphospholipid syndrome.
Yagi S; Nishiyama S; Abe T; Sata M
BMJ Case Rep; 2019 Jan; 12(1):. PubMed ID: 30635311
[TBL] [Abstract][Full Text] [Related]
16. Rivaroxaban Versus Warfarin and Risk of Post-Thrombotic Syndrome Among Patients with Venous Thromboembolism.
Søgaard M; Nielsen PB; Skjøth F; Kjældgaard JN; Coleman CI; Larsen TB
Am J Med; 2018 Jul; 131(7):787-794.e4. PubMed ID: 29476744
[TBL] [Abstract][Full Text] [Related]
17. Comparing Length of Stay Between Patients Taking Rivaroxaban and Conventional Anticoagulants for Treatment of Venous Thromboembolism.
Desai A; Desai A; Calixte R; Aparnath M; Hindenburg A; Salzman S; Mathew JP
Lung; 2016 Aug; 194(4):605-11. PubMed ID: 27192990
[TBL] [Abstract][Full Text] [Related]
18. Failure of dabigatran and rivaroxaban to prevent thromboembolism in antiphospholipid syndrome: a case series of three patients.
Schaefer JK; McBane RD; Black DF; Williams LN; Moder KG; Wysokinski WE
Thromb Haemost; 2014 Nov; 112(5):947-50. PubMed ID: 25118790
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism.
Coleman CI; Bunz TJ; Turpie AGG
Thromb Haemost; 2017 Oct; 117(10):1841-1847. PubMed ID: 28640322
[TBL] [Abstract][Full Text] [Related]
20. Direct Oral Anticoagulants Use in Antiphospholipid Syndrome: Are These Drugs an Effective and Safe Alternative to Warfarin? A Systematic Review of the Literature.
Dufrost V; Risse J; Zuily S; Wahl D
Curr Rheumatol Rep; 2016 Dec; 18(12):74. PubMed ID: 27812956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
